Drug delivery is the technology layer that decides how a peptide actually reaches its target. The most active threads on this site: oral peptide formulations (SNAC-based oral semaglutide, oral Wegovy, Vivtex's permeability platforms), microneedle and intranasal delivery, hydrogel and nanoparticle systems for sustained release, and AAV-based gene-therapy delivery for peptide therapeutics like MeiraGTx's AQP1 program for xerostomia.
The small-molecule oral GLP-1 wave (orforglipron / Foundayo) has reframed the conversation. Once you can deliver a non-peptide GLP-1 receptor agonist by mouth, the bioavailability ceiling on peptide orals matters less for that specific indication.
Stories here cover platform launches, validation papers, and partnership deals. See #oral-peptide, #oral-glp-1, and #nanomedicine for related threads.
A Nature Communications paper details crystalline mesoporous frameworks built from amphiphilic collagen-mimetic peptides (aCMPs) — charge-segregated collagen-mimetic sequences modified with lipid tails at their N-termini. Hydrophobic and electrostatic interactions drive 3D porous architectures whose lattice packing tracks with lipid-tail length (C12, C10, C8); shortening to C6 flips assembly into nanosheets. The work expands peptide-based biomaterials beyond the triple helix and offers a programmable scaffold platform for drug delivery and tissue engineering.
A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.
Sarfaraz K. Niazi at the University of Illinois Chicago College of Pharmacy published a March 20, 2026 review in Frontiers in Drug Delivery arguing oral peptide delivery success depends fundamentally on molecular pharmacology rather than formulation technology. The thesis: semaglutide's approval represents a rare boundary case enabled by its ~168-hour half-life and time-integrated pharmacodynamics, not a generalizable breakthrough. The author proposes a negative-selection framework identifying which peptides should be excluded from oral development — short elimination half-lives, dose sensitivity, regulatory variability constraints — and routes excluded candidates toward pulmonary, nasal, or long-acting injectable alternatives. The framework matters for the next-generation pipeline beyond Foundayo and Wegovy pill: many programs currently chasing oral delivery may be better served by alternative routes.
A team at Kumamoto University led by Associate Professor Shingo Ito developed a cyclic peptide (D-DNP-V) that ferries insulin across the small intestine. Combined with zinc-stabilized insulin hexamers and given orally to diabetes models, the platform rapidly normalized blood sugar with once-daily dosing for three consecutive days. A click-chemistry-conjugated DNP-insulin molecule performed equivalently, substantially reducing the high doses that have historically plagued oral insulin.
The Drug Discovery Chemistry Oral & Macrocyclic Peptides Summit (April 14-15, San Diego) convenes as 66 cyclic peptide drugs have gained global approval and the field races to solve oral bioavailability. Key advances include Chugai's Luna18 achieving 21-47% oral bioavailability and Merck's macrocyclic PCSK9 inhibitor enlicitide delivering injectable-level results in pill form.
A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.
Several peptide-loaded hydrogels are already in Phase 3 clinical trials for chronic and acute wound care, signaling an accelerating transition from bench to pharmacy shelf.
Researchers engineered PLGA nanocomplexes functionalized with iRGD tumor-penetrating peptides to deliver paclitaxel combined with medicinal fungus extract, targeting the PDCD4 gene to overcome drug resistance.